Breakthrough Prize 2026: Orkin & Thein Win $3M for BCL11A Discovery That Enabled Casgevy

At the 12th annual Breakthrough Prize ceremony in Los Angeles on April 18, 2026, Stuart H. Orkin (Harvard/Dana-Farber/HHMI) and Swee Lay Thein (NIH/National Heart, Lung and Blood Institute) are awarded the $3 million Breakthrough Prize in Life Sciences for elucidating the mechanism controlling the developmental switch from fetal to adult hemoglobin and validating BCL11A as a therapeutic target. Their foundational work — spanning the 1980s through 2010s — directly enabled Casgevy, the first FDA-approved CRISPR gene therapy (December 2023). Thein mapped hereditary persistence of fetal hemoglobin (HPFH) to chromosome 2 and identified BCL11A as the key molecular switch. Orkin demonstrated that BCL11A functions as the 'master repressor' of HbF and identified its erythroid-specific enhancer — the precise genomic element disrupted in Casgevy's editing strategy. A second Breakthrough Prize in Life Sciences goes to Jean Bennett, Katherine A. High, and Albert Maguire (University of Pennsylvania/CHOP) for developing Luxturna, the first FDA-approved gene therapy for a genetic disease (2017), for Leber congenital amaurosis — recognizing the broader gene therapy field. The 2026 Breakthrough Prize ceremony, attended by approximately $18.75M total prize distributions, marks the first year multiple prizes honor therapies that are now commercially approved.